SEC Comment Letter 0000000000-23-012266 to Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc.
Date: Nov. 8, 2023 · CIK: 0001636651 · Accession: 0000000000-23-012266
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275307
Letter
United States securities and exchange commission logo November 8, 2023 Jeremy M. Levin, DPhil, MB Chir Chief Executive Officer Ovid Therapeutics Inc. 441 Ninth Avenue, 14th Floor New York, New York 10001 Re:Ovid Therapeutics Inc. Registration Statement on Form S-3 Filed November 3, 2023 File No. 333-275307 Dear Jeremy M. Levin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Laura A. Berezin, Esq.
Show Raw Text
United States securities and exchange commission logo
November 8, 2023
Jeremy M. Levin, DPhil, MB Chir
Chief Executive Officer
Ovid Therapeutics Inc.
441 Ninth Avenue, 14th Floor
New York, New York 10001
Re:Ovid Therapeutics Inc.
Registration Statement on Form S-3
Filed November 3, 2023
File No. 333-275307
Dear Jeremy M. Levin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Laura A. Berezin, Esq.